Developing antibodies to fight COVID-19 using advanced technology
Official title: Structure-guided neutralizing antibodies developed using EpiVolve technology
Funded at Abbratech, INC. · NIH-11082180 · Data updated 2026-11-12
This study is working on developing special antibodies that can fight the COVID-19 virus, using a new method to make sure they can keep up with any changes the virus might make, which could help improve treatments for COVID-19 and other infections.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Abbratech, INC. NIH-funded |
| Lab location | 1 site (Branford, UNITED STATES) |
| Project start | May 5, 2023 |
| Project end | May 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $995,774 |
| NIH project number | 4R44AI177126-02 |
| Project ID | NIH-11082180 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who are at high risk for COVID-19 or those who have had severe reactions to the virus.
✕Less likely to help
Patients who are not at risk for COVID-19 or those who have already recovered without complications may not benefit from this research.
What this research studies
This research focuses on creating neutralizing antibodies that can effectively target the 2019 novel coronavirus. It employs a novel technology called EpiVolve, which systematically identifies and develops antibodies against specific sites on the virus. By overcoming immune tolerance and targeting virus-like epitopes, the approach aims to generate antibodies that can adapt to viral mutations. This could lead to more effective treatments for COVID-19 and potentially other infectious diseases.
Why it matters
Potential benefit: If successful, this research could lead to the development of highly effective antibodies that provide better protection against COVID-19.
How similar studies have gone: Other research has shown promise in developing antibodies using similar targeted approaches, indicating potential for success in this novel method.
Where this research is happening
-
Abbratech, INC.
Branford, United States Active
Researchers
- Principal investigator: Li, Xiaofeng — Abbratech, INC.
- Study coordinator: Li, Xiaofeng
Related research
Other NIH-funded projects on the same topics.
-
Antibody Platform for Protein Isoform Splice-Junctions
A fast-track NIH grant aims to create antibodies that specifically recognize unique splice-junctions in proteins, helping to better understand and treat diseases linked to alternative splicing.
-
Creating special antibodies to find disease-related protein changes
This project aims to create new tools, called antibodies, that can find specific changes in proteins linked to various diseases, including cancer.
-
Developing antibodies to target specific cancer mutations
This study is working on new antibodies that can help the immune system better recognize and attack cancer cells with a specific KRAS mutation, aiming to make treatments more effective and safer for patients with these types of cancers.
-
Developing antibodies to target specific protein splice variants
This study is working on a new way to find and test special antibodies that can help us understand and treat diseases like cancer by focusing on how proteins are made in different forms, which can change how they behave in the body.
-
Validating antibodies for detecting modified proteins
This study is working to make sure that the tools scientists use to find certain proteins in the lab are more accurate and reliable, which will help improve research and treatments for patients.
-
A platform for quickly creating and testing antibodies
This study is working on a new way to quickly create and test special proteins called antibodies that can help treat diseases, so patients can get better treatments faster and more effectively.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.